In addition, so far, IHC 0 and IHC 1+ have been frequently pooled under the broader definition of HER2-negative breast cancer, with HER2-0 prevalence widely ranging from 15% to 80% across studies. The gene discussed is ERBB2; the disease is breast carcinoma.